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Introduction: Recombinant factor VIII Fc fusion protein (rFVIIIFc) is a novel recombinant factor VIII with a prolonged
half-life, developed for the treatment of hemophilia A. Studies that evaluated the toxicological effects of rFVIIIFc in
2 pharmacologically relevant species, cynomolgus monkeys and Sprague Dawley rats, are reported here.
Materials and Methods: In repeat-dose toxicology studies, rats and monkeys received 0, 50, 250, or 1000 IU/kg
rFVIIIFc every other day for 4 weeks. In a high-dose tolerance study, monkeys received 1 rFVIIIFc dose of 3000,
10,000, or 20,000 IU/kg. Evaluations included in-life observations, laboratory and post-mortem evaluations,
pharmacokinetics, and local tolerance. Allometric scaling, using data from 4 animal species and humans, was used
to evaluate the relationship between animal and human pharmacokinetics.
Results: rFVIIIFc was well tolerated with no adverse toxicological ﬁndings directly attributable to rFVIIIFc. As
expected, antibodies to this fully humanprotein developed in rats andmonkeys in a time-dependent fashion follow-
ing repeated dosing, leading to increased clearance in both species. There were no local reactions (infusion site) or
evidence of thrombosis at high doses in rats andmonkeys. Allometric scaling demonstratedmore rapid clearance in
small animals compared with humans and a volume of distribution (steady state) proportional to body weight
across species, suggesting that animal pharmacokinetics are predictive of human pharmacokinetics.
Conclusions: Repeated doses of rFVIIIFc in 2 relevant animal species and high doses of rFVIIIFc inmonkeyswerewell
tolerated. These results supported the clinical safety of rFVIIIFc observed in phase 1/2a and phase 3 clinical trials.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hemophilia A is a hereditary bleeding disorder that results from
deﬁcient coagulation factor VIII (FVIII) activity [1]. It is characterized
by recurrent spontaneous or traumatic bleeding episodes, predomi-
nantly involving the joints and soft tissue [2,3]. Prophylactic treatment
with FVIII is considered the optimal therapy for peoplewith hemophilia
A, as it has been shown to reduce the frequency of joint hemorrhagesin time; AUC∞, area under the
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. This is an open access article underand destructive arthropathy [3,4]. However, the relatively short
half-lives of conventional recombinant FVIII (rFVIII) products necessi-
tates frequent infusions [4], which may limit adherence to treatment
regimens [5].
Recombinant factor VIII Fc fusion protein (rFVIIIFc) is a novel rFVIII
with a prolonged half-life [6]. rFVIIIFc is a recombinant protein
composed of a single rFVIII molecule that is covalently fused to the Fc
domain of human immunoglobulin G1 (IgG1) with no intervening link-
er sequence [6]. The Fc domain allows rFVIIIFc to bind the neonatal Fc
receptor (FcRn) [6], which is part of an endogenous pathway that delays
lysosomal degradation of Fc-containing proteins by cycling them back
into circulation, and thus extends their plasma half-life [7].
Both preclinical and clinical studies have evaluated the pharmacoki-
netics, efﬁcacy, and safety of rFVIIIFc. In preclinical studies, rFVIIIFc
demonstrated an approximately 2-fold increase in half-life and an
approximately 2-fold extension in the duration of prophylactic efﬁcacy
relative to rFVIII in animal models [8]. Phase 1/2a and phase 3 (A-LONG
study) clinical studies have also demonstrated the prolonged half-life of
rFVIIIFc in humans, with an approximately 1.5-fold increase in half-life
compared with rFVIII; the phase 3 study also demonstrated low
bleeding rates with rFVIIIFc when administered once to twice weekly
at doses of 25 to 65 IU/kg [9,10]. rFVIIIFc was well tolerated in both
clinical studies.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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systemic and local toxicological effects of repeat dosing of rFVIIIFc in
rats and monkeys, and the systemic toxicological effects of rFVIIIFc
followinghigh, single-dose administration inmonkeys. In addition, allo-
metric scaling was used to evaluate the relationship between animal
and human pharmacokinetic data for rFVIIIFc.
2. Materials and Methods
2.1. Study Drug
rFVIIIFc was produced using a stably transfected human embryonic
kidney (HEK) 293H host cell line [6,8]. rFVIIIFc was puriﬁed using a
multi-step puriﬁcation process, including afﬁnity chromatography as
well as anion exchange and hydrophobic interaction chromatography
steps [11].
2.2. Dosing Regimens
All animal activities were approved by the Institutional Animal Care
Committees and performed in accordancewith theGuide to the Care and
Use of Laboratory Animals [12].
2.2.1. Repeat-dose toxicology studies
The pharmacokinetics and toxicological effects (local and systemic)
of rFVIIIFc were evaluated following repeated doses of rFVIIIFc in
Sprague Dawley rats and cynomolgus monkeys in accordance with
Good Laboratory Practice (GLP) standards. One hundred Sprague
Dawley rats and 32 cynomolgus monkeys were included in the core
repeat-dose toxicology studies (Table 1). A separate satellite group of
120 rats (30 per dose group) was used for the pharmacokinetic and
immunogenicity analyses. Both rats and monkeys received intravenous
infusions of 0 (vehicle control), 50, 250, or 1000 IU/kg of rFVIIIFc every
other day for 4 weeks. Most animals were euthanized 2 days after the
last study dose (terminal necropsy on Day 29); a subset of animals in
the control and 1000 IU/kg dose groups (10 animals per dose group in
rats and 4 animals per dose group in monkeys) were euthanized
1 month after the last study dose (terminal necropsy on Day 57) to as-
sess recovery from potential adverse toxicological effects.Table 1
Non-clinical Toxicology Studies of rFVIIIFc in Rats and Monkeys.
Species Dose
(IU/kg)
N per groupa Regimen
Repeat-dose toxicology studies
Sprague Dawley rats 0 30b,c Every other day for 4 weeks
(total of 14 doses)50 20b
250 20b
1000 30b,c
Cynomolgus monkeys 0 10d Every other day for 4 weeks
(total of 14 doses)50 6
250 6
1000 10d
High-dose tolerance study
Cynomolgus monkeys 0 2 Once
3000 2
10,000 2
20,000 2
rFVIIIFc, recombinant factor VIII Fc fusion protein.
a Equal numbers of male and female animals in each group.
b Number of animals per group in toxicology cohorts. A satellite (separate) group of
animals (n = 30 per dose group; 15 male, 15 female) was used for the pharmacokinet-
ics and immunogenicity assessments in rats.
c Within this group, a recovery cohort comprising 10 animals (5 male, 5 female) was
examined 28 days after the last dose.
d Within this group, a recovery cohort comprising 4 animals (2 male, 2 female) was
examined 28 days after the last dose.2.2.2. High-dose tolerance study (single dose)
The pharmacokinetics and toxicological effects of high, single doses
of rFVIIIFcwere evaluated in a non-GLP study of 8 cynomolgusmonkeys
(Table 1). Monkeys received a single intravenous infusion of 0, 3000,
10,000, or 20,000 IU/kg of rFVIIIFc. The 20,000 IU/kg dose is approxi-
mately 300 times higher than the highest anticipated clinical dose. In
theory, doses above 3000 IU/kg likely exceed the binding capacity of
von Willebrand factor (VWF) for monkeys, assuming the molar ratio
of endogenous VWF to FVIII is 50:1 [13–15]. The potential for acute
thrombosis at these high doses of rFVIIIFc was assessed by monitoring
platelets and ﬁbrinogen (Supplementary Table 1). Monkeys were
euthanized 7 days after the single study dose, followed by terminal
necropsy.
2.3. Pharmacokinetics
Pharmacokinetic evaluations were performed in both the repeat-
dose toxicology and high-dose tolerance studies. In the repeat-dose
study performed in rats, animals were divided into subgroups for
pharmacokinetic sample collections due to limits on blood volume col-
lection. Each time point represents amean of 6 rats per group (3 rats per
sex per time point); because of this sparse sampling, pharmacokinetic
parameters were not derived for individual rats and as such, standard
deviations were not derived. Blood was collected following the ﬁrst
and last dose of rFVIIIFc on study Days 1 and 27, respectively, at 0.25,
1, 4, 8, 12, 24, 36, 48, 72, and 96 hours post-dose. In the repeat-dose
studies performed in monkeys, blood samples were collected both
pre-dose and post-dose (0.25, 1, 4, 8, 12, 24, 36, and 48 hours post-
dose) on Days 1 and 27. Plasma rFVIIIFc levels were measured by
enzyme-linked immunosorbent assay (ELISA). Pharmacokinetic analy-
sis was performed by Battelle (Columbus, OH), utilizing dosage and
concentration-time data for individual animals. Pharmacokinetic pa-
rameters were estimated with a non-compartmental model using
WinNonlin® software version 5.0.1 (Pharsight Corporation, Mountain
View, CA). The pharmacokinetic parameters evaluated and presented
here include: maximum plasma concentration (Cmax), area under the
curve up to the last measurable concentration (AUClast), elimination
half-life (t1/2), volume of distribution at steady state (Vss), clearance
(CL), and mean residence time (MRT).
In the high-dose tolerance study performed inmonkeys, blood sam-
ples were collected 0.25, 1, 8, 24, 48, 72, 96, and 120 hours post-dose.
Plasma rFVIIIFc levels were measured by ELISA. Pharmacokinetic analy-
sis was performed at Biogen (Cambridge, MA) using a 2-compartment
model in WinNonlin software version 5.3.
2.4. Toxicology
The toxicological effects of rFVIIIFcweremeasured through observa-
tions of in-life parameters (clinical observations, body weight, food
consumption, and ophthalmic examination), laboratory evaluations
(hematology, serum chemistry, and coagulation parameters), and
post-mortem evaluation (gross necropsy, organ weights, and histopa-
thology) in all studies. Cardiovascular evaluations were also performed
for monkeys in the repeat-dose toxicology study. Electrocardiograms
(ECGs) were recorded for all monkeys prior to dosing and on Day 23,
as well as in the week prior to the scheduled core cohort necropsy
(Day 26) and all recovery monkeys during the week prior (Day 54) to
the recovery cohort necropsy; ECGs were analyzed qualitatively by a
board-certiﬁed veterinary cardiologist. Heart rates were calculated
from the ECG tracings. Local tolerance was evaluated through gross
and microscopic evaluation of the intravenous infusion site in the
repeat-dose studies in both rats and monkeys.
Immunogenicity (formation of rFVIIIFc antibodies) was evaluated in
the satellite group of rats (n=24 per dose group) and in all monkeys in
the repeat-dose studies. Blood samples for immunogenicity evaluation
were drawn pre-study and on Days 11, 19, 27, and 57. Samples were
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at Prevalere Life Sciences, LLC (Whitesboro, NY).
2.5. Allometric Scaling
Allometric scaling (log-log plot) was utilized to evaluate the
relationship between body weight and both CL and Vss for rFVIIIFc.
Pharmacokinetic data from studies performed in 4 animal species
(mice, rats, monkeys, and dogs) and human subjects with hemophilia
Awere used for the analysis. Animal datawere derived from11 separate
pharmacokinetic proﬁles in mice (3-4mice per time point), 15 separate
pharmacokinetic proﬁles in rats, 58 individual proﬁles in monkeys, and
4 individual proﬁles in dogs [8]. Data for humans were obtained from
the phase 3 A-LONG clinical study (n = 27; pharmacokinetic parame-
ters derived from the chromogenic assay) [10].
2.6. Statistical Analysis
For the repeat-dose studies, assessments of in-life parameters, clini-
cal pathology, and post-mortem evaluations were analyzed statistically
when the number of animals was 3 or greater. Data were analyzed for
effects of rFVIIIFc through an analysis of variance. For data with
variances that were homogeneous across test groups, as determined
by Bartlett’s test for homogeneity at the 0.05 level, tests for differences
between experimental and control groups were made using Dunnett’s
test. For non-homogenous data, tests for pair-wise differences between
experimental and control groups were made using Cochran and Cox’s
modiﬁed 2-sample t test. Statistical signiﬁcance was set at the 0.05
level for all comparisons.
3. Results
3.1. Repeat-dose toxicology studies
3.1.1. Pharmacokinetics
For repeat-dose studies performed in rats, plasma pharmacokinetic
proﬁles followed a bi-exponential curve on Day 1. The Cmaxwas propor-
tional to rFVIIIFc dose; however, increases in AUClast were less than dose
proportional (Table 2). Mean t1/2 values varied among dose groups, and
ranged from 9.87 hours to 16.4 hours. Both CL and Vss values showed an
increasing trend as the rFVIIIFc dose increased. Following repeated dose
administration (Day 27), plasma concentrations of rFVIIIFc were unde-
tectable in approximately 60% of animals; this likely resulted from the
development of anti-rFVIIIFc antibodies in most rats (rFVIIIFc is a fullyTable 2
Pharmacokinetics of rFVIIIFc Following Repeat-dosing in Sprague Dawley Rats and Cynomolgu
Cmax
(μg/mL)
AUClast
(h · μg/mL)
Nb Day 1 Day 27c Day 1 Day 27c Da
Sprague Dawley rats
50 IU/kg 30d 0.0708 ND 0.945 ND 13
250 IU/kg 30d 0.417 ND 3.36 ND 16
1000 IU/kg 30d 1.09 ND 6.16 ND 9.8
Cynomolgus monkeys
50 IU/kg 6 0.153 ± 0.0148 0.140 ± 0.0586 2.08 ± 0.460 1.61 ± 1.25 12
250 IU/kg 6 0.872 ± 0.0289 0.438 ± 0.377e 11.3 ± 4.09 2.64 ± 4.31e 13
1000 IU/kg 10 3.76 ± 0.318 1.00 ± 1.55 45.1 ± 10.1 4.47 ± 10.7 11
rFVIIIFc, recombinant factor VIII Fc fusion protein; Cmax; maximum concentration; AUClast, area
CL, clearance; Vss, volume of distribution at steady state; NA, not applicable.
a Data from the rat study are presented as mean (due to sparse sampling, standard deviations w
b Equal numbers of male and female animals.
c Anti-rFVIIIFc antibodies developed in a dose-dependent fashion in rats and monkeys, whic
d Six rats (3 male, 3 female) were sampled per time point.
e n = 5.
f n = 2.
g n = 4.human protein). Therefore, pharmacokinetic parameters could not be
evaluated on Day 27 in rats.
In the repeat-dose studies performed in monkeys, plasma pharma-
cokinetic proﬁles also followed a bi-exponential curve on Day 1
(Fig. 1). Both Cmax and AUClast values were proportional to dose
(Table 2). Mean t1/2 values were comparable among dose groups and
ranged from 11.9 hours to 13.4 hours. Pharmacokinetic parameters
were similar between Day 1 and Day 27 in antibody-negativemonkeys;
however, the Cmax and AUClast were markedly lower and CL was mark-
edly higher in antibody-positive animals on Day 27. Because antibodies
in this group developed dose proportionally (occurred in 1/6 animals in
the low-dose group, 4/6 animals in the mid-dose group, and 6/10 ani-
mals in the high-dose group), changes in the pharmacokinetic parame-
ters were most prominent in the mid- and high-dose groups.
3.1.2. Toxicology
rFVIIIFc was well tolerated in both the rat and monkey repeat-dose
studies at all dose levels. There were no adverse toxicological ﬁndings
directly related to the effects of rFVIIIFc on any of the in-life parameters
evaluated in both species (Table 3). Cardiovascular evaluations demon-
strated heart rates and ECGs within normal limits for all dose levels of
rFVIIIFc. There were no adverse effects on laboratory parameters direct-
ly attributable to rFVIIIFc. Serum globulin levels, consisting primarily of
IgG, were not affected by rFVIIIFc. On Day 29, in male rats, mean globu-
lin levels were 2.2 g/dL in control animals and 2.4 g/dL, 2.2 g/dL, and
2.3 g/dL in the low-, mid-, and high-dose groups, respectively. Although
there was a statistically signiﬁcant difference (P b 0.05) in globulin
levels between the low-dose rFVIIIFc group and controls, the globulin
level reported for the low-dose group was within normal biological
limits. On Day 29, in female rats, there were no signiﬁcant differences
in globulin levels between groups (mean, 2.1 g/dL in all groups).
There were also no differences in globulin levels between experimental
and control groups in the rat study on Day 57 (recovery cohort; 0 and
1000 IU/kg dose groups evaluated), or in the monkey study on Day 29
(all dose groups) or Day 57 (recovery cohort; 0 and 1000 IU/kg dose
groups evaluated). There were also no adverse ﬁndings on post-
mortem analyses attributable to rFVIIIFc. There were no local tolerance
ﬁndings at the infusion site of rFVIIIFc in both rats andmonkeys,with no
local reactions found on gross or microscopic examinations. The no-
observed-adverse-effect level (NOAEL) was deﬁned as the highest
dose studied, 1000 IU/kg, in both rats and monkeys receiving repeated
doses of rFVIIIFc.
Anti-rFVIIIFc antibodies developed in a time-dependent fashion in
both rats and monkeys (Table 4). This was an expected ﬁnding, ass Monkeys.a
t1/2
(h)
CL
(mL/h/kg)
Vss
(mL/kg)
y 1 Day 27c Day 1 Day 27c Day 1 Day 27c
.4 ND 5.67 ND 110 ND
.4 ND 8.26 ND 196 ND
7 ND 21.6 ND 285 ND
.1 ± 2.18 10.9 ± 5.86e 2.85 ± 0.460 5.29 ± 5.43e 46.6 ± 9.66 46.1 ± 6.81e
.4 ± 2.79 7.15 ± NAf 3.17 ± 1.02 8.04 ± NAf 45.4 ± 10.3 47.2 ± NAf
.9 ± 1.86 4.21 ± 5.62g 3.19 ± 1.01 113 ± 125g 47.0 ± 6.51 93.3 ± 63.3g
under the curve up to the last measurable concentration; t1/2, half-life; ND, not detected;
ere not derived); data from themonkey study are presented as mean± standard deviation.
h resulted in more rapid elimination of rFVIIIFc on Day 27 compared with Day 1.
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Fig. 1. Pharmacokinetics of rFVIIIFc inmonkeys following a single intravenous dose onDay
1 of the 4-week repeat-dose toxicology study.a rFVIIIFc, recombinant factor VIII Fc fusion
protein; SD, standard deviation. aData represent mean ± SD.
Table 4
Incidence of Antibody Formation in Rats and Monkeys.
Day 1 Day 11 Day 19 Day 27 Day 57
(recovery group)a
Overallb
Ratsc
50 IU/kg 0/24 2/24 15/24 17/23 16/22 22/24
250 IU/kg 0/24 11/24 12/24 12/24 8/24 20/24
1000 IU/kg 1/24 14/24 16/24 6/24 6/24 22/24
Monkeys
50 IU/kg 0/6 0/6 1/6 1/6 // 1/6
250 IU/kg 0/6 0/6 2/6 4/6 // 4/6
1000 IU/kg 1/10 4/10 5/10 6/10 2/4 8/10
rFVIIIFc, recombinant factor VIII Fc fusion protein.
a In the rat study, all animals in the satellite pharmacokinetic/immunogenicity cohort
were included in the recovery assessment. In the monkey study, only a subgroup of
animals was included in the recovery assessment.
b Total number of animalswith conﬁrmed anti-rFVIIIFc antibodies at any time point (an
animal could have had conﬁrmed anti-rFVIIIFc antibodies at more than 1 time point).
c One control rat also tested positive in the antibody assay on Day 1.
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development was not associated with gender or dose level (with the
exception of a dose-dependence observed on Day 11). Most (~70%) an-
tibody responses for rats were speciﬁc to the FVIII moiety of rFVIIIFc;
speciﬁcity for Fc was not tested due to limited sample availability
(although the formation of antibodies speciﬁc for Fc would not be an
unexpectedﬁnding, as the Fcmoiety of rFVIIIFc is derived froma protein
foreign to rats, human IgG1). By Day 19, a majority of rats in all dose
groups had developed antibodies, with 15, 12, and 16 out of 24 animals
in the low-, mid-, and high-dose groups, respectively, testing positive
for antibodies. Nearly all of the animals developed antibodies during
the course of the study; however, presence was transient for some ani-
mals. Interestingly, 14 of 24 and 16 of 24 rats in the high-dose group
were positive for antibodies on Days 11 and 19, respectively, but only
6 of these animals also tested positive on Days 27 and 57. A summary
of antibody incidence for individual rats is described in Supplementary
Table 2. Cross-reactivity between anti-rFVIIIFc antibodies and endoge-
nous FVIII was likely responsible for an approximately 20% to 25%
increase in the activated partial thromboplastin time (aPTT) that was
observed inmales receiving themid dose andmales and females receiv-
ing the high dose on Day 29 compared with controls; increases in aPTT
did not result in any adverse clinical events in rats.
Formonkeys, antibody developmentwas both time and dose depen-
dent. On Day 11, only monkeys in the high-dose group (4/10) had
developed anti-rFVIIIFc antibodies (Table 4). By Day 27, the majority
of monkeys in themid-dose (4/6) and high-dose (6/10) groups had de-
veloped antibodies (only 1/6 monkeys in the low-dose group wasTable 3
Repeat-dose Toxicity in Sprague Dawley Rats and Cynomolgus Monkeys.
In-life parameters
Clinical
observations
Food
consumption
BW Ophthalmic
exam
ECG HR Coagulation
parameters
Rats WNL WNL WNL WNL NA NA ~20%-25%
increase in aP
high-dose gro
Monkeys Limb and/or
body
discoloration in
2 mid- and
7 high-dose
group monkeysb
NA WNL WNL WNL WNL PTWNL
aPTT increase
mid- and high
groupsb
BW, body weight; ECG, electrocardiogram; HR, heart rate; WNL, values within normal limits fo
with controls; NA, not applicable; aPTT, activatedpartial thromboplastin time; PT, prothrombin t
a Changes in aPTT did not result in adverse clinical signs in rats.
b Findings in clinical observations, gross pathology, and histopathology, and elevations in aPT
with cross-reactivity to endogenous FVIII.positive at this time). Data for individual monkeys are reported in Sup-
plementary Table 3. All antibodies were speciﬁc to the FVIII moiety of
rFVIIIFc (none were speciﬁc to only the Fc portion). Cross-reactivity be-
tween these anti-rFVIIIFc antibodies and endogenous rFVIII was likely
responsible for several observed clinical, laboratory, and pathological
abnormalities occurring in the mid- and high-dose groups, including
subcutaneous hemorrhaging following venipuncture with resultant
limb and/or body discoloration (2 monkeys in the mid-dose group
and 7 monkeys in the high-dose group) and decreases in red blood
cell mass (1 monkey in the mid-dose group and 5 monkeys in the
high-dose group had a decrease in hemoglobin levels of ≥2.3 g/dL on
Day 29 compared with pre-dose levels). Increases in aPTTwere also ob-
served, which supports the notion that antibodies to rFVIIIFc cross-
reacted with endogenous FVIII. Of note, 1 animal each in the high-
dose groups from both the rat and monkey studies tested positive for
anti-rFVIIIFc antibodies on Day 1; however, these results are unlikely
to indicate an antibody response to rFVIIIFc because the signals mea-
sured in these animals were just above the assay cut-point.
3.2. High-dose Tolerance Study (Single Dose)
Pharmacokinetic parameters that were observed following a high,
single-dose infusion of rFVIIIFc in cynomolgus monkeys are shown in
Table 5. Plasma proﬁles followed a bi-exponential curve (Fig. 2). Al-
though Cmax remained approximately proportional to dose at these
high-dose levels, AUC was non-linear despite the lack of signiﬁcant
change in the terminal elimination half-life. Other pharmacokineticLaboratory evaluations Post-mortem evaluation
Hematology
parameters
Serum
chemistry
Organ
weight
Gross
pathology
Histo-
pathology
TT in
upsa,b
WNL WNL WNL WNL WNL
in
-dose
Hemoglobin,
RBC count, and
hematocrit decreased in
1 monkey in the mid-
and 5 monkeys in the
high-dose groupsb
WNL WNL Subcutaneous
hemorrhageb
Skin,
acute
hemorrhageb
r control animals, with no noteworthy ﬁndings in experimental animals when compared
ime; RBC, red blood cell; rFVIIIFc, recombinant factor VIII Fc fusion protein; FVIII, factor VIII.
T and decreases in hemoglobinwere likely due to the formation of anti-rFVIIIFc antibodies
Table 5
Single-dose Pharmacokinetics of rFVIIIFc Following High-dose Infusion in Cynomolgus
Monkeys.
Dose
(IU/kg)
Na MRT
(h)
AUC∞
(h · μg/mL)
Cmax
(μg/mL)
t1/2
(h)
Vss
(mL/kg)
CL
(mL/h/kg)
3000 2 15.9 21.2 4.7 13.3 262 16.3
10,000 2 10.8 27.2 15.5 12.8 419 38.6
20,000 2 10.0 55.8 33.7 14.2 444 42.0
rFVIIIFc, recombinant factor VIII Fc fusion protein; MRT, mean residence time; AUC∞, area
under the curve from zero to time inﬁnity; Cmax, maximum plasma concentration;
t1/2, half-life; Vss, volume of distribution at steady state; CL, clearance.
a One male and female animal per group. Averages are reported.
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level, varied among these 3 dose groups. The observed non-linearity is
likely due to the FVIII concentration exceeding the binding capacity of
VWF; as a result, much of the rFVIIIFc would not be protected by VWF
and would be cleared more rapidly at the higher-dose levels (eg, CL at
20,000 IU/kg was 42.0 mL/h/kg). The potential thrombogenicity
of very high doses of rFVIIIFc tested in monkeys, including a
20,000 IU/kg dose that is 300 times higher than the highest anticipated
clinical dose, was assessed by monitoring platelets and ﬁbrinogen
(Supplementary Table 1). No evidence for depletion of platelets or ﬁ-
brinogen was observed when compared with either pre-dose levels
or historical reference range values for platelet counts (223 to 475 x
103/μL) or ﬁbrinogen (173 to 413mg/dL) as determined for cynomolgus
monkeys. No increases in mean platelet volume were observed when
compared to pre-dose or reference values (7.9 to 11.5 fL), indicating
that platelets were not destroyed by high doses of rFVIIIFc.
These high, single doses of rFVIIIFcwerewell tolerated. Therewas no
effect of rFVIIIFc on laboratory parameters, including indicators of
thrombogenicity, or post-mortem pathology. The NOAEL was deﬁned
as the highest studied dose, 20,000 IU/kg.
3.3. Allometric Scaling
The experimentally derived allometric scaling equations and log-log
plots for CL and Vss are shown in Fig. 3. The allometric scaling equations
derived for CL and Vss suggest that animal pharmacokinetic results are
predictive of human pharmacokinetic results for rFVIIIFc. Based on the
exponents (0.91 for CL; 0.95 for Vss), rFVIIIFcwasmore rapidly eliminat-
ed in small animals compared with humans, and the Vss was propor-
tional to body weight; this is consistent with the pattern for other
biotherapeutic molecules [16,17]. Although the data for monkeys align
with the allometric scaling curve for rFVIIIFc using the 4 other speciesrF
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4. Discussion
Here, we report the results from preclinical studies assessing the
pharmacokinetics and toxicological effects of rFVIIIFc, and the applica-
bility of animal-derived pharmacokinetic data to humans. The toxico-
logical effects of rFVIIIFc were evaluated in 4-week, repeat-dose
studies in both rats and monkeys and in a high, single-dose tolerance
study in monkeys, using doses up to 300-fold higher than the highest
anticipated clinical dose.
Rats andmonkeyswere pharmacologically relevant species for these
studies, as the coagulation cascade is well conserved across species and
rFVIIIFc is able to bind to FcRn in both species (unpublished data). The
route of administration (intravenous) and formulations of rFVIIIFc
used in this study were consistent with those used in clinical studies;
the lyophilized formulation used in the repeat-dose monkey study
was representative of the formulation intended for commercial use.
Dosing frequency in the repeat-dose studies (every other day) was
based on an elimination half-life of approximately 13 hours in both spe-
cies. The doses of rFVIIIFc used in these studies (50-1000 IU/kg in the
repeat-dose studies and 3000-20,000 IU/kg in the high-dose study)
were greater than those indicated for use in humans (25-65 IU/kg
[18,19]).
rFVIIIFc was well tolerated in repeat-dose studies in rats and mon-
keys and in the high, single-dose tolerance study in monkeys. There
were no adverse toxicological effects (in-life parameters, laboratory
evaluation, and post-mortem evaluation) directly attributable to
rFVIIIFc at the highest doses tested in all studies (1000 IU/kg in the
repeat-dose studies, 20,000 IU/kg in the high, single-dose study); ad-
verse effects that were observed with high doses of rFVIIIFc in the
repeat-dose studies were likely due to the development of antibodies
with cross-reactivity to endogenous FVIII, which was an expected ﬁnd-
ing, as described below. There were no adverse effects of rFVIIIFc found
during cardiac evaluation, including heart rate and ECGs, in monkeys.
No local tolerance ﬁndings were observed on gross or microscopic
examinations.
rFVIIIFc did not affect immunoglobulin levels in the repeat-dose
studies; this is important as the Fc component of rFVIIIFc binds to
the same receptor as IgG [20]. The concentration of IgG in serum from
adults and children ranges from 520 to 1630 mg/dL [21], and the
nominal speciﬁc activity of rFVIIIFc ranges from approximately 8000
to 10,000 IU/mg [8,22]. In the repeat-dose studies reported here, the
highest rFVIIIFc dose of 1000 IU/kg produced Cmax values in rats andmon-
keys of 0.109 mg/dL and 0.376 mg/dL, respectively; in the high, single-
dose study in monkeys, the maximum rFVIIIFc dose (20,000 IU/kg) led
to a Cmax value of 3.37 mg/dL. Furthermore, in the phase 1/2a clinical
study of rFVIIIFc, a dose of 65 IU/kg produced a mean Cmax of 103 to
136 IU/dL (0.010-0.014mg/dL) [9]. Based on these results, in a therapeu-
tic dose range (eg, 65 IU/kg), the serum concentration of rFVIIIFc is sub-
stantially lower than that of endogenous IgG. Thus, the lack of effect of
rFVIIIFc on immunoglobulin levels was expected.
Adverseﬁndings observed in the repeat-dose studieswere related to
anti-rFVIIIFc antibody development, which was an expected ﬁnding
given that rFVIIIFc is a fully human protein, foreign to both animal spe-
cies. Antibody development occurred in a time-dependent fashion in
both rats andmonkeys, andwas dose-dependent inmonkeys. These an-
tibodies acted as “clearing” antibodies in many animals, which resulted
in more rapid rFVIIIFc elimination in the later portion of the study in
comparison with rFVIIIFc elimination following the ﬁrst dose. This lim-
ited rFVIIIFc exposure in the latter portion of the study for some animals
and, as a result, it was not feasible to conduct toxicology studies beyond
4 weeks. The antibodies cross-reacted with endogenous FVIII, resulting
in prolonged coagulation time in both rats and monkeys and increased
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Thus, the elevations in aPTT and changes in hematology parameters
(due to blood loss from acute and/or chronic hemorrhage) observed in
some monkeys at higher doses of rFVIIIFc were considered secondary
to anti-rFVIIIFc antibody development. Moreover, there was no organ
toxicity secondary to antibody/antigen complex formation as evidenced
by a lack of histopathological changes in rats or monkeys treated with
rFVIIIFc. The development of antibodies that cross-react with endoge-
nous FVIII has previously been reported during preclinical trials of
other B-domain deleted FVIII and full-length FVIII products [23,24]. In
addition, an immune tolerance induction study in hemophilia A mice
showed that, when administered at therapeutic doses, rFVIIIFc is
capable of actively promoting immune tolerance to FVIII [25].
Plasma pharmacokinetic proﬁles demonstrated a bi-exponential
curve for rFVIIIFc in both the repeat-dose and high, single-dose studies.
In the repeat-dose studies, both Cmax and AUCwere approximately pro-
portional to dose over awide range of doses, while t1/2 did not varywith
dose. In these repeat-dose studies, rFVIIIFc pharmacokinetics were sim-
ilar after multiple dose administrations in animals that did not develop
antibodies. In the high, single-dose study with 3000, 10,000, and
20,000 IU/kg of rFVIIIFc, there was a more rapid distribution phase,
which was likely reﬂective of an excess of rFVIIIFc in relation to the
VWF concentration, resulting in markedly increased Vss and CL, as
well as reduced dose-normalized Cmax and AUC. This is consistent
with a biodistribution study, which demonstrated that rFVIIIFc, likeendogenous FVIII, is stabilized in circulation by VWF; furthermore, the
biodistribution study also demonstrated that the liver is the major
clearance organ for rFVIIIFc, and that the presence of VWF delays liver
uptake of rFVIIIFc from the blood [26].
In this study, allometric scaling demonstratedmore rapid CL in small
animals compared with humans, and a Vss that was proportional
to body weight across 4 animal species (mice, rats, monkeys, and
dogs) and humans. Similar results have been reported with other
biotherapeutic products [16,17]. The exponent for CL obtained in this
study (0.91) was higher than the exponent of CL previously reported
in an early allometric scaling study of rFVIII (0.69) [17], but was similar
to values previously reported for other biotherapeutic proteins and
small molecules (typical range of 0.6-0.8; several biotherapeutic pro-
teins have exponents ranging from 0.90-1.05) [17,27,28]. Furthermore,
in a recentmeta-analysis utilizing 100 published pharmacokinetic stud-
ies of human FVIIImolecules (both plasma-derived and recombinant) in
mice, rats, rabbits, dogs,monkeys, and humans, the allometric exponent
observed for CL (0.85) [28] is in better agreementwith the exponentwe
report for rFVIIIFc compared with that reported in the earlier study of
rFVIII [17]. The allometric exponent for Vss in the present study of
rFVIIIFc (0.95) was within the range of previously reported values for
other biotherapeutic products and small molecules, including rFVIII
(range, 0.8-1.1) [16,17,29], and is very similar to the exponent reported
for FVIII (0.97) in the meta-analysis of FVIII pharmacokinetic studies
[28]. These data suggest that pharmacokinetic results in animals are
1272 J.A. Dumont et al. / Thrombosis Research 136 (2015) 1266–1272predictive of pharmacokinetic results for rFVIIIFc in individuals with
hemophilia A.
5. Conclusions
rFVIIIFc was well tolerated in 2 relevant animal species, rats and
monkeys. An adequate safety margin of 10-fold was demonstrated,
based on a NOAEL of 1000 IU/kg in the repeat-dose toxicology studies
comparedwith a highest anticipated clinical dose of 100 IU/kg. The non-
clinical safety proﬁle of rFVIIIFc shown here supported the observed
clinical safety proﬁle of rFVIIIFc [9,10]. Furthermore, the A-LONG
phase 3 clinical study demonstrated that rFVIIIFc was well tolerated
and efﬁcacious for the prevention and treatment of bleeding episodes
in previously treated subjects with severe hemophilia A [10].
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